Report overview
The IDO (indoleamine 2,3-dioxygenase 1, IDO1, IDO-1, INDO, indoleamine-pyrrole 2,3-dioxygenase) inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global IDO inhibitors market. Most of the pipeline therapeutics are in early stage of development, the market is yet to witness first IDO inhibitor launch and its impact on overall oncology market.
This report aims to provide a comprehensive presentation of the global market for IDO Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding IDO Inhibitors. This report contains market size and forecasts of IDO Inhibitors in global, including the following market information:
Global IDO Inhibitors Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global IDO Inhibitors Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five IDO Inhibitors companies in 2022 (%)
The global IDO Inhibitors market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Indoleamine-2,3-dioxygenase (IDO) is one of the many immune checkpoints in tumor immune escape. Inhibiting IDO will help researchers restore immune system responses, which in turn, will help identify and destroy cancer cells. In addition to transforming the approach to treat advanced melanoma, the successful entry of IDO inhibitors in the market will also help transform the treatment of non-small lung cancer, triple-negative breast cancer, and bladder cancer with the existing therapies. Currently, most of the IDO inhibitors under investigation are in the very nascent development stage and focusing on R&D, pharmaceutical companies are making huge investments through collaboration agreements. For instance, one of the major pharmaceutical companies Pfizer has partnered with iTeos Therapeutics for the development of undisclosed IDO1 and tryptophan 2,3-dioxygenase 2 (TDO2) inhibitors.
We surveyed the IDO Inhibitors manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global IDO Inhibitors Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global IDO Inhibitors Market Segment Percentages, by Type, 2022 (%)
Dual IDO1/TDO inhibitors
Covalent IDO inhibitors
Global IDO Inhibitors Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global IDO Inhibitors Market Segment Percentages, by Application, 2022 (%)
Metastatic Melanoma
Metastatic Pancreatic Cancer
mCRPC
Malignant Glioma
Astrocytoma
Breast Cancer
Global IDO Inhibitors Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global IDO Inhibitors Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies IDO Inhibitors revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies IDO Inhibitors revenues share in global market, 2022 (%)
Key companies IDO Inhibitors sales in global market, 2018-2023 (Estimated), (K Units)
Key companies IDO Inhibitors sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Bristol-Myers Squibb
Kyowa Hakko Kirin
Outline of Major Chapters:
Chapter 1: Introduces the definition of IDO Inhibitors, market overview.
Chapter 2: Global IDO Inhibitors market size in revenue and volume.
Chapter 3: Detailed analysis of IDO Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of IDO Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global IDO Inhibitors capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
